Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gneiss, C
Right arrow Articles by Deisenhammer, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gneiss, C
Right arrow Articles by Deisenhammer, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 10, No. 5, 507-510 (2004)
DOI: 10.1191/1352458504ms1074oa

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity

C Gneiss

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

M Reindl

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

A Lutterotti

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

R Ehling

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

R Egg

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

M Khalil

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

T Berger

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

F Deisenhammer

Department of Neurology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria, florian.deisenhammer{at}uibk.ac.at

Background: It has been reported that in some patients with MS who develop neutralizing antibodies (NAbs) against interferon beta (IFNb), antibody levels can initially increase and then decrease thereafter even when treatment is continued. Objective: To determine whether NAb titre correlates with time to reversion to NAb negativity in patients with multiple sclerosis (MS). Methods: Twenty-eight patients with MS who were NAb-positive during treatment with one of the currently available IFNbs were included in this retrospective study. NAb titres were determined by the myxovirus resistance protein A induction assay. Patients were considered NAb-positive if they had at least two consecutive samples with titres of]/20 neutralizing units (NU). Reversion to NAb-negative status was defined as two consecutive negative samples (NAb titre of B/20 NU) after NAb positivity. Results: When measured two years after treatment initiation, a NAb titre of B/75 NU had a 91.7% sensitivity and a 87.5% specificity for reversion to NAb negativity in the following two years (after a total of four years of treatment). In addition, somewhat surprisingly, patients whose serum converted to NAb-negative generally developed peak NAb titres earlier than patients who remained NAb-positive (mean time of first detection was 21 versus 38 months, respectively). Conclusion: The NAb titre might support treatment decisions in patients with MS whose test results are positive for NAbs.

Key Words: interferon beta • multiple sclerosis • neutralizing antibodies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
P. Soelberg Sorensen
Review: Neutralizing antibodies against interferon-beta
Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141.
[Abstract] [PDF]

Home page
 Mult SclerHome page
P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen
Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies?
Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. A Farrell and G. Giovannoni
Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis
Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577.
[Abstract] [PDF]

Home page
 Mult SclerHome page
A. AL-Sabbagh
Neutralizing antibodies in MS therapy: reviewing the Rebif experience
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 8 - 13.
[Abstract] [PDF]

Home page
 Mult SclerHome page
F. Deisenhammer
Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-{beta} therapy
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 44 - 48.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al.
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737.
[Abstract] [PDF]